Alpelisib (BYL719)

For research use only. Not for use in humans.

目录号:S2814 中文名称:阿培利司

Alpelisib (BYL719) Chemical Structure

CAS No. 1217486-61-7

Alpelisib (BYL719) 是一种有效的选择性PI3Kα抑制剂,在无细胞试验中IC50为 5 nM,对PI3Kβ/γ/δ具有极弱的作用。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 4864.29 现货
RMB 3034.22 现货
RMB 4650.12 现货
RMB 7115.91 现货
RMB 10401.3 现货
RMB 13677.3 现货
RMB 21867.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Alpelisib (BYL719)发表文献114篇:

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Alpelisib (BYL719) 是一种有效的选择性PI3Kα抑制剂,在无细胞试验中IC50为 5 nM,对PI3Kβ/γ/δ具有极弱的作用。Phase 2。
靶点
PI3Kα [1]
(Cell-free assay)
5 nM
体外研究

BYL719抑制含有PIK3CA突变体的乳腺癌细胞系的增殖,与PI3K/Akt通路各种下游信号组分的抑制相关。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Detroit562 NFWzeHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWCwMlEuOTByIN88US=> MYi3NkBp MV3JR|UxRTFwMUCg{txO MoPNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUC1OFkoRjJ3NUWwOVQ6RC:jPh?=
SNU-1076 MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOwMlEuOTByIN88US=> MXO3NkBp NH7ETIFKSzVyPU[uPFIh|ryP M2PMblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUWwOVQ6Lz5{NUW1NFU1QTxxYU6=
SNU-1066 NUjXVnh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILuVooxNjFvMUCwJO69VQ>? MnS4O|IhcA>? M3v3XGlEPTB;MT6xN{DPxE1? M{X3NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUWwOVQ6Lz5{NUW1NFU1QTxxYU6=
FaDu NGfMZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rxUlAvOS1zMECg{txO M4jHRVczKGh? MXvJR|UxRTF7Lk[2JO69VQ>? MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV3MEW0PUc,OjV3NUC1OFk9N2F-
SNU1041 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLhNE4yNTFyMDFOwG0> M4nwelczKGh? MUjJR|UxRTJyLk[1JO69VQ>? NIHUfY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1NFU1QSd-MkW1OVA2PDl:L3G+
SCC25 NX7LTlN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHLNE4yNTFyMDFOwG0> M4nT[FczKGh? NXLOdpR7UUN3ME20PU4{OCEQvF2= MlztQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUC1OFkoRjJ3NUWwOVQ6RC:jPh?=
BON-1 NWK4U3NETnWwY4Tpc44hSXO|YYm= NHSwUo0yNzFyIN88US=> MkLuOEBp Mn\EbY5pcWKrdIOgVGk{UyBqQVvUJHNmejNyODmgZY5lKG2WT2LDNU8zKGGldHn2bZRq\XN? NETOTXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCyOlI6Oid-MkWwNlYzQTJ:L3G+
QGP-1 MmH5SpVv[3Srb36gRZN{[Xl? MYmxM|ExKM7:TR?= NIXa[4U1KGh? NHrOZ5hqdmirYnn0d{BRUTONIDjBT3QhW2W{M{C4LUBidmRibWTPVmMyNzJiYXP0bZZqfGmncx?= M3rDS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEK2NlkzLz5{NUCyOlI6OjxxYU6=
MG-63 MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1v5XmlEPTB;NjFOwG3wxIxiSVO5NF0zPCEQvF2= NHjreWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm2NVc6OCd-MkS5OlE4QTB:L3G+
HOS NXntOGxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvtTWM2OD1zNTFOwG3wxIxiSVO5NF01OiEQvF2= MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl4MUe5NEc,OjR7NkG3PVA9N2F-
MOS-J MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jZU2lEPTB;MUCg{txO97zOIFnDPVA:OzZizszN NWX1epFIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlE4QTBpPkK0PVYyPzlyPD;hQi=>
POS-1 NYr4b3k3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYryXoVlUUN3ME24JO69Ve,:jDDJR|kxRTN4IN88US=> NVnZdlZJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlE4QTBpPkK0PVYyPzlyPD;hQi=>
92.1 MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TtNFUxOC1{MECwJI5O M3LYXlUh\A>? MnHtbY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2SgLHNmejR5MzmgeZAhfG9iMTFOwG0> NEjY[Jo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW2N|U1OCd-MkS1OlM2PDB:L3G+
Mel270 NEm4SpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\vVJA2ODBvMkCwNEBvVQ>? MkfWOUBl NH3B[lZqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHLWEApW2W{NEezLUB2eCC2bzCxJO69VQ>? MlrHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NkO1OFAoRjJ2NU[zOVQxRC:jPh?=
Omm1.3 MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknxOVAxNTJyMECgcm0> MX:1JIQ> MXHpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVDCoV4VzPDd|KTD1dEB1dyBzIN88US=> NV:1[o5jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OlM2PDBpPkK0OVY{PTRyPD;hQi=>
Omm1 Mlf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXpOVAxNTJyMECgcm0> MoDWOUBl MlvmbY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2SgLHNmejR5MzmgeZAhfG9iMTFOwG0> NWrOcZBsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OlM2PDBpPkK0OVY{PTRyPD;hQi=>
C918 NXzCVmdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDoOVAxNTJyMECgcm0> NEDrSJo2KGR? M1fSXIlvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvUJEhU\XJ2N{OpJJVxKHSxIEGg{txO MnjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NkO1OFAoRjJ2NU[zOVQxRC:jPh?=
Mel290 NEjNUZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYm1NFAuOjByMDDuUS=> MYe1JIQ> MWrpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVDCoV4VzPDd|KTD1dEB1dyBzIN88US=> NHvzeYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW2N|U1OCd-MkS1OlM2PDB:L3G+
OPM2 NETMUIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUSwMlUuOi53IN88US=> MUO0PEBp MVrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MmDFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MEWxNlEoRjJ2NEC1NVIyRC:jPh?=
OPM1 Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHSxUIwxNjVvMj61JO69VQ>? NFX6[Y01QCCq MlW4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRyNUGyNUc,OjR2MEWxNlE9N2F-
U266 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrHZ|BbOC53LUKuOUDPxE1? M1fTSlQ5KGh? M371SIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1rkfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEC1NVIyLz5{NESwOVEzOTxxYU6=
MM1R M{jmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYD2[mdJOC53LUKuOUDPxE1? M4Do[lQ5KGh? NGTsOJhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHX1OlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESwOVEzOSd-MkS0NFUyOjF:L3G+
MM1S Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrxOIVlOC53LUKuOUDPxE1? M2SwclQ5KGh? MmXXbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRyNUGyNUc,OjR2MEWxNlE9N2F-
H929 M1rSNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[wMlUuOi53IN88US=> NIHVZ3Y1QCCq MV7pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRyNUGyNUc,OjR2MEWxNlE9N2F-
RPMI MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn6wNE42NTJwNTFOwG0> NGewNIc1QCCq M1TyTYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Moj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MEWxNlEoRjJ2NEC1NVIyRC:jPh?=
SKBR3 NGm5dXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYqxfodQOzNizszN M{TJTFUh\A>? NVHSV|NZcW6qaXLpeJMhOzYxvJWgZ4VtdCCpcn;3eIg> NILwc4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
MDA453 NHjPPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCzN{DPxE1? NGjkS5g2KGR? NVXWcndXcW6qaXLpeJMhOzkxvJWgZ4VtdCCpcn;3eIg> M1;VUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
EFM192A NFznZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrkdJN[OzNizszN MYq1JIQ> M{Pz[olvcGmkaYTzJFI497zHIHPlcIwh\3Kxd4To NGrWVII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
AU565 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlS3N|Mh|ryP Mk\qOUBl MUXpcohq[mm2czCyOw+9jSClZXzsJIdzd3e2aB?= MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlzOEe5O{c,OjN7MUi3PVc9N2F-
MDA361 NVTv[Yp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWezN{DPxE1? MoL2OUBl MYTpcohq[mm2czC0OQ+9jSClZXzsJIdzd3e2aB?= MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlzOEe5O{c,OjN7MUi3PVc9N2F-
BT474 NV7XZ|N{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrvN|Mh|ryP MnfZOUBl MoPjbY5pcWKrdIOgNVbwxIViY3XscEBoem:5dHi= MlP2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ|OUG4O|k4RC:jPh?=
HCC202 M1zMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHIb|c{OyEQvF2= NH7pXHE2KGR? MV;pcohq[mm2czCyNQ+9jSClZXzsJIdzd3e2aB?= Mn7EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ|OUG4O|k4RC:jPh?=
KPL4 MoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojvN|Mh|ryP NXrxOop5PSCm NFHjRZhqdmirYnn0d{A2QO,:hTDj[YxtKGe{b4f0bC=> NYP2R|h{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVg4QTdpPkKzPVE5Pzl5PD;hQi=>
NCL-N87 MkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml62N|Mh|ryP MnLEOUBl NGrMTVBqdmirYnn0d{A{Oe,:hTDj[YxtKGe{b4f0bC=> NIXZPWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
UACC812 MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHNbFRjOzNizszN NEDPcVg2KGR? NFu5bHhqdmirYnn0d{AzP+,:hTDj[YxtKGe{b4f0bC=> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlzOEe5O{c,OjN7MUi3PVc9N2F-
HCC2218 M1LrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXPWWU{OyEQvF2= Mn2wOUBl NVLiTINZcW6qaXLpeJMhOTYxvJWgZ4VtdCCpcn;3eIg> MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzlzOEe5O{c,OjN7MUi3PVc9N2F-
HCC1569 Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjreo9EOzNizszN MoPEOUBl MWrpcohq[mm2czC189yGKGOnbHyg[5Jwf3Sq NIrsNow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mxPFc6Pyd-MkO5NVg4QTd:L3G+
OE19 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVGzN{DPxE1? Ml7pOUBl M2PhPIlvcGmkaYTzJFI{97zHIHPlcIwh\3Kxd4To MmnjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ|OUG4O|k4RC:jPh?=
OE33 NYXQbpVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHqN|Mh|ryP MlvuOUBl NXrEUHRpcW6qaXLpeJMhOjQxvJWgZ4VtdCCpcn;3eIg> M{nmeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
JIMT1 Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXwdYlyOzNizszN NH;zcIk2KGR? NY\DV5Z7cW6qaXLpeJMhQe,:hTDj[YxtKGe{b4f0bC=> NXKyeHpYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVg4QTdpPkKzPVE5Pzl5PD;hQi=>
HCC1954 M4LHeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjIXpE{OyEQvF2= NUOxdFRCPSCm M{KxeIlvcGmkaYTzJFI697zHIHPlcIwh\3Kxd4To NVq5fHIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVg4QTdpPkKzPVE5Pzl5PD;hQi=>
NUGC4 NHrzPFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuzN{DPxE1? NWTxNFRZPSCm NW\vSm14cW6qaXLpeJMhOTUxvJWgZ4VtdCCpcn;3eIg> Mn65QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7MUi3PVcoRjJ|OUG4O|k4RC:jPh?=
ZR-75-30 MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrwTFk{OyEQvF2= NUDhU5RlPSCm M2jBR4lvcGmkaYTzJE0yPe,:hTDj[YxtKGe{b4f0bC=> M4rGOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OUG4O|k4Lz5{M{mxPFc6PzxxYU6=
Rat1 M{fqN3AyOTCjbIDoZUBqdmirYnn0bY9vKGG|c3H5 MXnJR|UxKD1iMD6wO|Qh|ryP M2TOe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MU[0NVg6Lz5{NkG2OFE5QTxxYU6=
Rat1 NIjReVJRUTONYXzwbIEhcW6qaXLpeIlwdiCjc4PhfS=> NHq2SIFKSzVyIE2gNE4xPzRizszN MlnRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{ME[1NFQoRjJ4MkC2OVA1RC:jPh?=
Rat1 NYXK[mR5WDFzMHHsdIhiKGmwaHnibZRqd25iYYPzZZk> M4H5SWlEPTBiPTCwMlA4PCEQvF2= NUDrZnN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NlYxOzRpPkKzO|I3ODN2PD;hQi=>
Rat1 M2PjUnAyOTCmZXz0ZUBqdmirYnn0bY9vKGG|c3H5 M1nuZWlEPTBiPTCxMlIh|ryP NHf5e2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG2OFE5QSd-Mk[xOlQyQDl:L3G+
Rat1 M4DT[HBKO0upYX3tZUBqdmirYnn0bY9vKGG|c3H5 NH3FfG9KSzVyIE2gNU4zKM7:TR?= MoGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{ME[1NFQoRjJ4MkC2OVA1RC:jPh?=
Rat1 M{fRe3AyOTCmZXz0ZUBqdmirYnn0bY9vKGG|c3H5 NHTUO5ZKSzVyIE2gNU4zKM7:TR?= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{NkCzOEc,OjN5Mk[wN|Q9N2F-
Rat1 NYDacJJVWDFzMHLleIEhcW6qaXLpeIlwdiCjc4PhfS=> M3nYSGlEPTBiPTCyMlIh|ryP MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF4NEG4PUc,OjZzNkSxPFk9N2F-
Rat1 MmfwVGk{U2KndHGgbY5pcWKrdHnvckBie3OjeR?= NWjIdG1uUUN3MDC9JFIvOiEQvF2= NFjkUog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKwOlUxPCd-Mk[yNFY2ODR:L3G+
Rat1 MlHxVFEyOGGucHjhJIlvcGmkaYTpc44h[XO|YYm= MWnJR|UxKD1iMj6yJO69VQ>? NHfSZ449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyOlA{PCd-MkO3NlYxOzR:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT(S473) / p-AKT(T308); 

PubMed: 25544637     


PIK3CA hot-spot mutant cell lines were treated with 1 µM BYL719 for the indicated period of time. Lysates were immunoblotted to detect the indicated proteins.

p100β / p110α / p85 / p-ERBB3(Y1289); 

PubMed: 25544637     


BT474 cells were treated with 1 µM BYL719 alone for different durations of time and lysates were immunoprecipitated with ERBB3 antibody. Precipitates were analyzed by western blot with the indicated antibodies.

p-HER2 / IGF-1R; 

PubMed: 25544637     


Cells were treated with 1 μM BYL719 for 24 hr and lysates were immunoblotted to detect the indicated proteins.

pS6 (Ser235-236); 

PubMed: 27048245     


Immunoblots of lysates from parental and resistant cells treated for 24 hours as indicated.

PIM1 / PIM2 / PIM3 / p-PRAS40 / p-RPS6 / p-BAD; 

PubMed: 27604488     


T47D cells cultured to resistance in the presence of BYL719. Both parental (T47D) and resistant (T47DR) cells were treated with BYL719 at 1μM, and cell lysates were prepared at 0, 4, 24 hours for immunoblotting for the indicated proteins.

25544637 27048245 27604488
Growth inhibition assay
Cell viability; 

PubMed: 27602501     


The effect of BYL719 on cellular viability was evaluated in HCT116 (A) and SW480 (B) CRC cells. Briefly, cells were grown, treated with increasing concentrations of BYL719 (5, 10 and 20 μM) and cellular viability determined by MTS assay 72h after treatments. Controls included cells that remained untreated (media ctrl) and vehicle-treated controls (DMSO). Data represent means ± SEM of at least triplicate experiments normalized to controls. All conditions were compared with DMSO. Ctrl, control; DMSO, dimethyl sulfoxide. **, p< 0.01; ***, p< 0.001; ****, p< 0.0001.

27602501
Immunofluorescence
LC3; 

PubMed: 26637440     


SKBR3 GFP-LC3 cells were cultured for 5 days with DMSO, 500 nM BKM120 or 500 nM BYL719. Cells were treated with DMSO or 1 μM Lapatinib for the final 18 h. GFP-LC3 localization was captured by fluorescent microscopy.

26637440
体内研究 BYL719(>270 mg/d)在PIK3CA突变体异种移植啮齿动物模型中表现出统计学显著的剂量依赖性抗肿瘤效能。BYL719具有低清除率,半衰期为8.5小时,并且它的作用在30mg/d 和450mg/d之间剂量成比例的增加,在人的Cmax 和AUC中显示出低的个体差异。BYL719(270mg/d)首次表现出临床疗效的迹象,包括在ER+乳腺癌患者中证实的部分响应,以及17个患者中8个实现了显著的PET响应(PMR)和/或肿瘤治愈。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 88 mg/mL (199.33 mM)
Ethanol 2 mg/mL (4.53 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
4.4 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 441.47
化学式

C19H22F3N5O2S

CAS号 1217486-61-7
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04589650 Not yet recruiting Drug: Alpelisib|Drug: Placebo PIK3CA-related Overgrowth Spectrum (PROS) Novartis Pharmaceuticals|Novartis February 2 2021 Phase 2
NCT04544189 Not yet recruiting Drug: Alpelisib|Drug: Fulvestrant|Drug: Placebo Breast Neoplasms Novartis Pharmaceuticals|Novartis December 31 2020 Phase 2
NCT04524000 Recruiting Drug: Alpelisib|Drug: Fulvestrant Advanced Breast Cancer Novartis Pharmaceuticals|Novartis November 20 2020 Phase 2
NCT04300790 Recruiting Drug: Alpelisib|Drug: Metformin|Drug: Fulvestrant Breast Cancer MedSIR|Novartis October 23 2020 Phase 2
NCT04526470 Not yet recruiting Drug: Alpelisib|Drug: Paclitaxel Solid Tumor|Stomach Cancer Seoul National University Bundang Hospital September 1 2020 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买Alpelisib (BYL719) | Alpelisib (BYL719)供应商 | 采购Alpelisib (BYL719) | Alpelisib (BYL719)价格 | Alpelisib (BYL719)生产 | 订购Alpelisib (BYL719) | Alpelisib (BYL719)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID